Business

Multicorp International, Inc Acquires 70% Ownership in Patented Migraine Headache Medication

Multicorp International, Inc Acquires 70% Ownership in Patented Migraine Headache Medication.

articleMulticorp International, Inc.December 17, 20135/company/multicorp-intl-inc/news/multicorp-international-inc-acquires-70percent-ownership-in-patented-migraine-headache-medication
Multicorp International, Inc Acquires 70% Ownership in Patented Migraine Headache Medication

About this update from Multicorp International, Inc.

[{"type":"text","content":"\n \n \n Multicorp International, Inc Acquires 70% Ownership in Patented Migraine Headache Medication\n \n \nMulticorp International, Inc Acquires 70% Ownership in Patented Migraine Headache Medication\n\nCompany Seeking Clinical Trial Partner to Begin Testing in First Quarter of 2014\n\n \n SUN VALLEY, CA--(Marketwired - Dec 17, 2013) - MultiCorp International, Inc, (OTC Pink: MCIC) has acquired a 70% stake in a patented migraine medication. The company released the following statement:\n \"MultiCorp International, Inc has acquired a 70% ownership in a patented migraine medicine that has shown to aid in the symptoms of migraine headaches. According to www.migraine.com in the U.S. alone more than 37 million people suffer from migraines and globally over 330 million people have migraines on a constant basis. The medication was developed by a physician that MultiCorp will work closely with in order to gain FDA approval for the medication. The company plans to begin clinical trials in the first quarter of 2014 and hope to have the medication to market as soon as possible. The information on the patent can be found at http://www.faqs.org/patents/app/20090018205. Under the terms of the agreement, MultiCorp will have full authority to oversee the clinical trials of the product, marketing and selling of the medication, as well the overall business of getting the product to market as quickly as possible and retaining a 70% interest in the product. With the average cost of $145 per month in medication for migraine sufferers, the market for this product is exponential here in the U.S. and globally.\"\n For companies wishing to assist MultiCorp in clinical trials, please email us at [email protected]\n About MultiCorp International, Inc. \n MultiCorp International, Inc is a diverse company that operates in various business sectors that show true growth potential. The company builds on its executives experience in property development, constructions, medical, hospitality, agribusiness, commodities such as oil and gas, and entertainment. The company looks to expand through acquisitions of solid business models and management that have the potential to grow exponentially. The company will have additional subsidiaries that will eventually grow into being their own public entity, be sold, or continue to operate within MultiCorp. F...

More updates from Multicorp International, Inc.